MAB5206
Anti-Amyloid Antibody, β 1-16, clone DE2
culture supernatant, clone DE2, Chemicon®
Sign Into View Organizational & Contract Pricing
All Photos(3)
Anti-AAA, Anti-ABETA, Anti-ABPP, Anti-AD1, Anti-APPI, Anti-CTFgamma, Anti-CVAP, Anti-PN-II, Anti-PN2, Anti-alpha-sAPP, Anti-preA4
Recommended Products
biological source
mouse
Quality Level
antibody form
culture supernatant
antibody product type
primary antibodies
clone
DE2, monoclonal
species reactivity
monkey, bovine, human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
immunohistochemistry: suitable (paraffin)
western blot: suitable
isotype
IgG
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... APP(351)
Application
Anti-Amyloid Antibody, β 1-16, clone DE2 is an antibody against Amyloid for use in ELISA, WB, IH(P).
Western blot: 1:10-1:300 Immunohistochemistry: 1:10-1:200 on formaldehyde fixed, paraffin embedded tissue, requires formic acid or microwave pretreatment to stain Alzheimer′s brain senile plaques. ELISA Immunoprecipitation
Optimal working dilutions must be determined by end user.
Optimal working dilutions must be determined by end user.
Physical form
Culture supernatant. Liquid containing 0.02% sodium azide.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
WGK
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Acta neuropathologica, 141(5), 651-666 (2021-03-08)
The farnesyltransferase inhibitor, Lonafarnib, reduces tau inclusions and associated atrophy in familial tauopathy models through activation of autophagy, mediated by the inhibition of farnesylation of the Ras GTPase, Rhes. While hinting at a role of Rhes in tau aggregation, it
Scientific reports, 13(1), 19828-19828 (2023-11-15)
Photobiomodulation (PBM), the process of exposing tissue to red or near-infrared light, has become a topic of great interest as a therapy for diverse pathologies, including neurodegenerative disorders. Here, we aimed to evaluate the potential beneficial effect of PBM on
Neuromolecular medicine, 3(1), 29-39 (2003-04-01)
Studies of amyloid precursor protein transgenic mice suggest that immune responses to amyloid beta peptide (Abeta) may be instrumental in the removal of plaques from the brain, but the initial clinical trial of an Abeta vaccine in patients with Alzheimer
S100A9 knockout decreases the memory impairment and neuropathology in crossbreed mice of Tg2576 and S100A9 knockout mice model.
Testing null
Alzheimer's & dementia : the journal of the Alzheimer's Association, 18(11), 2099-2116 (2022-01-26)
In Alzheimer's disease (AD), the distribution of the amyloid precursor protein (APP) and its fragments other than amyloid beta, has not been fully characterized. Here, we investigate the distribution of APP and its fragments in human AD brain samples and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service